The effects of tolvaptan on renal handling of water and sodium, vasoactive hormones and circulatory system, during basal conditions and during inhibition of the nitric oxide system in healthy subjects. A dose-response study.
Phase of Trial: Phase II
Latest Information Update: 03 Mar 2017
Price : $35 *
At a glance
- Drugs Tolvaptan (Primary)
- Indications Hyponatraemia; Kidney disorders
- Focus Pharmacodynamics
- Acronyms DOVA
- 31 Aug 2018 Biomarkers information updated
- 20 Dec 2014 Status changed from active, no longer recruiting to completed as reported by EU Clinical Trials Register record.
- 08 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.